Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

16 Apr 2026 15:00

Faron Pharmaceuticals Ltd | Company announcement | April 16, 2026 at 18:00:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuerx
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsx
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rightsx
Other (please specify) iii: Dividend payments in kind.
3. Details of person subject to the notification obligation iv
NameTimo Syrj¤l¤
City and country of registered office (if applicable)Monaco
4. Full name of shareholder(s) (if different from 3.) v
NameAcme Investments SPF Sarl
City and country of registered office (if applicable)Luxembourg
5. Date on which the threshold was crossed or reached vi:15.4.2026
6. Date on which issuer notified (DD/MM/YYYY):16.4.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached7.77%15.509.433
Position of previous notification (ifapplicable)12.69%14.697.112
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rights
Direct(DTR5.1)Indirect(DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)
FI40001533095.949.3209.560.1132.98%4.79%
SUBTOTAL 8. A15.509.4337.77%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiNumber of voting rights that may be acquired if the instrument isexercised/converted.% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiPhysical or cashSettlement xiiNumber of voting rights% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivX
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Timo Syrj¤l¤ (Direct)2.98%2.98%
Acme Investments SPF Sarl (Indirect)4.79%4.79%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information Faron share issue during April 2026
Place of completionMonaco
Date of completion16.4.2026
Date   Source Headline
2nd Mar 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
25th Feb 20217:00 amRNSNotice of Full-Year Results and Annual Report
17th Feb 20214:30 pmRNSHolding(s) in Company
12th Feb 20213:00 pmRNSRegistration of Placing Shares
12th Feb 20217:00 amRNSResults of Placing and Issue Price
11th Feb 20214:30 pmRNSProposed Issue and Placing of Shares
26th Jan 20217:00 amRNSUpdate on TRAUMAKINE development
20th Jan 20212:06 pmRNSSecond Price Monitoring Extn
20th Jan 20212:01 pmRNSPrice Monitoring Extension
20th Jan 20217:00 amRNSBexmarilimab (Clevegen) development update
18th Jan 20212:05 pmRNSSecond Price Monitoring Extn
18th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Jan 202111:06 amRNSSecond Price Monitoring Extn
18th Jan 202111:01 amRNSPrice Monitoring Extension
18th Jan 20217:00 amRNSUS Department of Defense to support TRAUMAKINE
4th Jan 20217:00 amRNSFaron to Present at H.C. Wainwright
21st Dec 20207:00 amRNSFaron’s financial calendar for 2021
10th Dec 20207:00 amRNSPresents at ESMO Immuno-Oncology Virtual Congress
23rd Nov 20207:30 amRNSTo Participate in Upcoming Investor Conferences
23rd Nov 20207:00 amRNSBexmarilimab (Clevegen) development update
20th Nov 20207:00 amRNSIssue of Equity
16th Oct 202011:35 amRNSFirst Results from WHO Solidarity Trial
14th Oct 20202:15 pmRNSGrant of options
30th Sep 20209:45 amRNSHolding(s) in Company
24th Sep 20207:15 amRNSExercise of options
24th Sep 20207:00 amRNSHalf-year Report
18th Sep 20207:00 amRNSMATINS trial data presented at ESMO
9th Sep 202012:00 pmRNSFaron to Present at H.C. Wainwright Conference
27th Aug 20207:00 amRNSNotice of Half-Year Report
18th Aug 20207:00 amRNSTraumakine Update
17th Aug 20204:41 pmRNSSecond Price Monitoring Extn
17th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Jul 20207:00 amRNSChange of Adviser
20th Jul 20204:41 pmRNSSecond Price Monitoring Extn
20th Jul 20204:35 pmRNSPrice Monitoring Extension
8th Jul 20203:00 pmRNSManagers’ transactions
16th Jun 20207:01 amRNSFaron hosts virtual R&D Day today
16th Jun 20207:00 amRNSFaron update on pipeline progress ahead of R&D Day
15th Jun 20207:00 amRNSFaron receives EUR 2.1 million funding from BF
11th Jun 20207:00 amRNSFaron selected for EUR2.5 million grant from EIC
1st Jun 20207:00 amRNSMATINS Update
28th May 20207:00 amRNSFaron announces R&D Day to be held in June
20th May 20207:00 amRNSPublication in Intensive Care Medicine
18th May 20204:00 pmRNSResults of the Annual General Meeting
13th May 20201:00 pmRNSExercise of options
12th May 20206:00 pmRNSManagers’ transactions
11th May 202010:00 amRNSFaron receives grant from Business Finland
5th May 20207:00 amRNSClevegen manufacturing agreement
29th Apr 20201:15 pmRNSHolding(s) in Company
27th Apr 20202:45 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.